Compare MAN & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAN | MPLT |
|---|---|---|
| Founded | 1948 | 2018 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 1994 | N/A |
| Metric | MAN | MPLT |
|---|---|---|
| Price | $32.77 | $28.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $35.67 | $32.67 |
| AVG Volume (30 Days) | ★ 790.6K | 266.0K |
| Earning Date | 04-16-2026 | 05-28-2026 |
| Dividend Yield | ★ 4.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $17,957,100,000.00 | N/A |
| Revenue This Year | $5.12 | N/A |
| Revenue Next Year | $3.42 | N/A |
| P/E Ratio | $646.00 | ★ N/A |
| Revenue Growth | ★ 0.58 | N/A |
| 52 Week Low | $25.15 | $12.24 |
| 52 Week High | $47.34 | $33.28 |
| Indicator | MAN | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 62.10 | 51.12 |
| Support Level | $28.29 | $26.20 |
| Resistance Level | $40.27 | $31.88 |
| Average True Range (ATR) | 1.51 | 2.15 |
| MACD | 0.42 | -0.18 |
| Stochastic Oscillator | 91.91 | 62.68 |
ManpowerGroup Inc provides workforce solutions and services, including recruitment and assessment, upskilling, reskilling, training and development, career management, outsourcing, and workforce consulting. The company leverages its trusted brands, industry knowledge, and AI-enabled assessments and offers an extensive portfolio of training and leadership development solutions. Its reportable segments are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others, with Staffing and Interim generating the majority of revenue. It operates in the Americas, Southern Europe, Northern Europe, and APME. The company derives the maximum geographical revenue from the Southern European region.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.